Skip to main content

Table 2 Risks of developing NAFLD in relation to FM/FFM ratio by sex and obesity status

From: Fat mass to fat-free mass ratio and the risk of non-alcoholic fatty liver disease and fibrosis in non-obese and obese individuals

  Quartile 1 Quartile 2 Quartile 3 Quartile 4 p for trend Per 1 SD increment p value
Men (n = 1017)
 Non-obesity (n = 612)
  Model 1 Reference 1.32 (0.65–2.71) 1.47 (0.73–2.98) 3.17 (1.66–6.04) < 0.001 1.59 (1.28–1.98) < 0.001
  Model 2 1.19 (0.57–2.48) 1.24 (0.60–2.57) 2.80 (1.44–5.42) 0.001 1.55 (1.23–1.95) < 0.001
  Model 3 0.89 (0.42–1.91) 0.92 (0.43–1.97) 1.61 (0.79–3.28) 0.127 1.27 (0.99–1.63) 0.064
 Obesity (n = 405)
  Model 1 Reference 1.35 (0.73–2.50) 1.66 (0.90–3.04) 2.65 (1.46–4.81) 0.001 1.37 (1.12–1.69) 0.003
  Model 2 1.40 (0.74–2.64) 1.51 (0.81–2.83) 2.52 (1.35–4.71) 0.004 1.33 (1.08–1.65) 0.009
  Model 3 1.23 (0.64–2.39) 1.23 (0.64–2.38) 2.15 (1.11–4.18) 0.028 1.25 (0.99–1.58) 0.064
Women (n = 2402)
 Non-obesity (n = 1569)
  Model 1 Reference 1.47 (0.91–2.39) 2.06 (1.30–3.26) 3.08 (1.98–4.78) < 0.001 1.44 (1.24–1.66) < 0.001
  Model 2 1.57 (0.96–2.57) 2.21 (1.38–3.54) 3.27 (2.07–5.16) < 0.001 1.44 (1.24–1.67) < 0.001
  Model 3 1.29 (0.78–2.16) 1.77 (1.08–2.91) 2.35 (1.44–3.81) < 0.001 1.28 (1.10–1.50) 0.002
 Obesity (n = 833)
  Model 1 Reference 1.12 (0.74–1.72) 1.25 (0.82–1.90) 1.72 (1.14–2.59) 0.009 1.24 (1.08–1.44) 0.003
  Model 2 1.20 (0.78–1.85) 1.29 (0.84–1.99) 1.93 (1.27–2.94) 0.002 1.29 (1.12–1.50) 0.001
  Model 3 1.14 (0.73–1.79) 1.13 (0.72–1.79) 1.63 (1.05–2.55) 0.039 1.22 (1.04–1.42) 0.013
  1. Data are odds ratio (OR) and 95% confidence interval (CI)
  2. P values were calculated from the logistic regression models. Model 1 was crude model. Model 2 adjusted for age, current smoking, current drinking, active physical activity, and education level. Model 3 further adjusted for fasting glucose, HOMA-IR, triglycerides, LDL-C, HDL-C, white blood cells based on model 2
  3. FM/FFM fat-to-fat free mass ratio, OR odds ratio, CI confidence interval, SD standard deviation, HOMA-IR homeostasis model assessment of insulin resistance, HDL-C high density lipoprotein cholesterol, LDL-C low density lipoprotein cholesterol
\